Predictors of therapeutic response to haloperidol in acute schizophrenia

Joseph Patrick McEvoy, N. R. Schooler, W. H. Wilson

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

During a study of neuroleptic threshold haloperidol doses as treatment for newly admitted schizophrenic patients, we examined whether variables extracted from patients' clinical histories, the type and severity of patients' psychopathology at baseline, or the emergence of specific extrapyramidal side effects (EPSE) during treatment were associated with therapeutic response. Rapid therapeutic response was most powerfully predicted by a short (less than 1 month) duration of active illness prior to admission. Severe psychopathology at baseline, or the development of akathisia at neuroleptic threshold doses, portended against early response. More gradual therapeutic response was also associated with limited (less than 6 months) duration of active illness prior to admission. Motor retardation at baseline also characterized late responders. Active illness for more than 6 months prior to admission, greater chronicity of overall course, and heavy nicotine consumption characterized nonresponders.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalPsychopharmacology Bulletin
Volume27
Issue number2
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Haloperidol
Schizophrenia
Psychopathology
Antipsychotic Agents
Therapeutics
Psychomotor Agitation
Nicotine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Predictors of therapeutic response to haloperidol in acute schizophrenia. / McEvoy, Joseph Patrick; Schooler, N. R.; Wilson, W. H.

In: Psychopharmacology Bulletin, Vol. 27, No. 2, 01.01.1991, p. 97-101.

Research output: Contribution to journalArticle

@article{23d28cc7cc5f44a0a928e5028507a4bb,
title = "Predictors of therapeutic response to haloperidol in acute schizophrenia",
abstract = "During a study of neuroleptic threshold haloperidol doses as treatment for newly admitted schizophrenic patients, we examined whether variables extracted from patients' clinical histories, the type and severity of patients' psychopathology at baseline, or the emergence of specific extrapyramidal side effects (EPSE) during treatment were associated with therapeutic response. Rapid therapeutic response was most powerfully predicted by a short (less than 1 month) duration of active illness prior to admission. Severe psychopathology at baseline, or the development of akathisia at neuroleptic threshold doses, portended against early response. More gradual therapeutic response was also associated with limited (less than 6 months) duration of active illness prior to admission. Motor retardation at baseline also characterized late responders. Active illness for more than 6 months prior to admission, greater chronicity of overall course, and heavy nicotine consumption characterized nonresponders.",
author = "McEvoy, {Joseph Patrick} and Schooler, {N. R.} and Wilson, {W. H.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "27",
pages = "97--101",
journal = "Psychopharmacology Service Center bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "2",

}

TY - JOUR

T1 - Predictors of therapeutic response to haloperidol in acute schizophrenia

AU - McEvoy, Joseph Patrick

AU - Schooler, N. R.

AU - Wilson, W. H.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - During a study of neuroleptic threshold haloperidol doses as treatment for newly admitted schizophrenic patients, we examined whether variables extracted from patients' clinical histories, the type and severity of patients' psychopathology at baseline, or the emergence of specific extrapyramidal side effects (EPSE) during treatment were associated with therapeutic response. Rapid therapeutic response was most powerfully predicted by a short (less than 1 month) duration of active illness prior to admission. Severe psychopathology at baseline, or the development of akathisia at neuroleptic threshold doses, portended against early response. More gradual therapeutic response was also associated with limited (less than 6 months) duration of active illness prior to admission. Motor retardation at baseline also characterized late responders. Active illness for more than 6 months prior to admission, greater chronicity of overall course, and heavy nicotine consumption characterized nonresponders.

AB - During a study of neuroleptic threshold haloperidol doses as treatment for newly admitted schizophrenic patients, we examined whether variables extracted from patients' clinical histories, the type and severity of patients' psychopathology at baseline, or the emergence of specific extrapyramidal side effects (EPSE) during treatment were associated with therapeutic response. Rapid therapeutic response was most powerfully predicted by a short (less than 1 month) duration of active illness prior to admission. Severe psychopathology at baseline, or the development of akathisia at neuroleptic threshold doses, portended against early response. More gradual therapeutic response was also associated with limited (less than 6 months) duration of active illness prior to admission. Motor retardation at baseline also characterized late responders. Active illness for more than 6 months prior to admission, greater chronicity of overall course, and heavy nicotine consumption characterized nonresponders.

UR - http://www.scopus.com/inward/record.url?scp=0025739955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025739955&partnerID=8YFLogxK

M3 - Article

C2 - 1924667

AN - SCOPUS:0025739955

VL - 27

SP - 97

EP - 101

JO - Psychopharmacology Service Center bulletin

JF - Psychopharmacology Service Center bulletin

SN - 0048-5764

IS - 2

ER -